St. Jude's CEO to Give 2009 Rennebohm Lecture: September 10
At 9:45am he will speak in 2002 Rennebohm Hall on "A 30-year Evolution from Pharmacokinetics to Pharmacogenomics: Where to Next?"
He will also deliver a second lecture of special interest to those in the cancer community, "Pharmacogenomics of Acute Lymphoblastic Leukemia: From Discovery to Clinical Practice." That lecture will also take place in room 2002 Rennebohm Hall at 1pm.
A reception will be held immediately following the final lecture in the Rennebohm Hall Commons.
Dr. Evans is well known for his 30 years of research focusing on the effect of chemotherapy in children with cancer, particularly for the individualization of treatment. His research on the pharmacodynamics and pharmacogenomics of anticancer agents in children looks at the genetic and biochemical mechanisms underlying differences in drug effects among children.
Dr. Evans has been honored for his contributions to the field, including three consecutive MERIT Awards from the National Institutes of Health and several national and international awards. Dr. Evans has also published more than 300 research articles and book chapters and has been invited to speak at more than 200 universities.
Evans received his doctoral degree (PharmD) from the University of Tennessee and spent a sabbatical year at the University of Basel (1987-1988) studying pharmacogenomics. He received an honorary doctor of science degree (honoris causa) from The Ohio State University in 2008.
Date Published: 08/26/2009